PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS
ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple st...
Saved in:
Published in: | Arquivos de gastroenterologia Vol. 58; no. 2; pp. 139 - 144 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE
01-06-2021
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVE: To analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODS: This is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTS: A total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSION: TyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery.
RESUMO CONTEXTO: A doença hepática gordurosa não-alcoólica (DHGNA) é a doença hepática mais prevalente no mundo. Nos Estados Unidos, a DHGNA já é a segunda causa de transplante hepático. O espectro da doença abrange desde a esteatose simples, que apresenta curso benigno, até esteato-hepatite não-alcoólica (EHNA), que pode progredir para cirrose e suas complicações. O desenvolvimento de métodos não invasivos para o diagnóstico e estadiamento da EHNA e da fibrose hepática visa diminuir a necessidade de biópsia hepática, um procedimento invasivo e não raro associado a complicações. OBJETIVO: Analisar o desempenho do índice triglicerídeo-glicose (TyG Index) para o diagnóstico e estadiamento da DHGNA em pacientes obesos. MÉTODOS: Este é um estudo transversal retrospectivo. Foram analisados todos os prontuários de pacientes candidatos a cirurgia bariátrica em um hospital de referência do Sul do Brasil e calculado o TyG Index, um escore composto por dois exames laboratoriais (triglicerídeos e glicose de jejum), realizados previamente à cirurgia. O desempenho do TyG Index em relação aos achados anatomopatológicos hepáticos foi avaliado, e calculada a curva ROC para avaliação de esteatose simples, EHNA e fibrose hepática. O NAFLD Fibrosis Score (NFS) também foi avaliado. RESULTADOS: Foram avaliados 423 pacientes. O melhor ponto de corte do TyG Index para a exclusão de esteatose simples significativa (grau 2-3) foi de 8,76, com sensibilidade 67,6%, especificidade 65,1%, valor preditivo positivo (VPP) 46,3%, valor preditivo negativo (VPN) 81,8%, acurácia 65,8% e AUROC 0,66 (P=0,005). Na avaliação de EHNA significativa (grau 2-3), o melhor ponto de corte foi de 8,82 com sensibilidade 57,3%, especificidade 58,6%, VPP 33,7%, VPN 78,8%, acurácia 58,8% e AUROC 0,58 (P=0,022). Em relação à fibrose avançada (grau 3-4), o melhor ponto de corte do TyG Index foi de 8,91 com sensibilidade 61,8%, especificidade 62,5%, VPP 13,8%, VPN 94,4%, acurácia 62,4% e AUROC 0,69 (P<0,001). Ao analisarmos o desempenho do NFS no diagnóstico de fibrose avançada, o ponto de corte de <-1,455 excluiu fibrose avançada com sensibilidade 59,4%, especificidade 51%, VPP 11%, VPN 92,4% e acurácia 51,7%. Entretanto, o ponto de corte de 0,676 para fibrose avançada apresentou sensibilidade de 21,9%, especificidade 83%, VPP 11,7%, VPN 91,2% e acurácia 77,3%. A AUROC foi de 0,54 (P=0,480). CONCLUSÃO: O TyG Index não apresentou bom desempenho para o diagnóstico e estadiamento da esteatose simples e da EHNA. Entretanto, foi capaz de excluir fibrose avançada em pacientes obesos candidatos a cirurgia bariátrica. |
---|---|
AbstractList | ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVE: To analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODS: This is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTS: A total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSION: TyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery. ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVE: To analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODS: This is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTS: A total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSION: TyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery. RESUMO CONTEXTO: A doença hepática gordurosa não-alcoólica (DHGNA) é a doença hepática mais prevalente no mundo. Nos Estados Unidos, a DHGNA já é a segunda causa de transplante hepático. O espectro da doença abrange desde a esteatose simples, que apresenta curso benigno, até esteato-hepatite não-alcoólica (EHNA), que pode progredir para cirrose e suas complicações. O desenvolvimento de métodos não invasivos para o diagnóstico e estadiamento da EHNA e da fibrose hepática visa diminuir a necessidade de biópsia hepática, um procedimento invasivo e não raro associado a complicações. OBJETIVO: Analisar o desempenho do índice triglicerídeo-glicose (TyG Index) para o diagnóstico e estadiamento da DHGNA em pacientes obesos. MÉTODOS: Este é um estudo transversal retrospectivo. Foram analisados todos os prontuários de pacientes candidatos a cirurgia bariátrica em um hospital de referência do Sul do Brasil e calculado o TyG Index, um escore composto por dois exames laboratoriais (triglicerídeos e glicose de jejum), realizados previamente à cirurgia. O desempenho do TyG Index em relação aos achados anatomopatológicos hepáticos foi avaliado, e calculada a curva ROC para avaliação de esteatose simples, EHNA e fibrose hepática. O NAFLD Fibrosis Score (NFS) também foi avaliado. RESULTADOS: Foram avaliados 423 pacientes. O melhor ponto de corte do TyG Index para a exclusão de esteatose simples significativa (grau 2-3) foi de 8,76, com sensibilidade 67,6%, especificidade 65,1%, valor preditivo positivo (VPP) 46,3%, valor preditivo negativo (VPN) 81,8%, acurácia 65,8% e AUROC 0,66 (P=0,005). Na avaliação de EHNA significativa (grau 2-3), o melhor ponto de corte foi de 8,82 com sensibilidade 57,3%, especificidade 58,6%, VPP 33,7%, VPN 78,8%, acurácia 58,8% e AUROC 0,58 (P=0,022). Em relação à fibrose avançada (grau 3-4), o melhor ponto de corte do TyG Index foi de 8,91 com sensibilidade 61,8%, especificidade 62,5%, VPP 13,8%, VPN 94,4%, acurácia 62,4% e AUROC 0,69 (P<0,001). Ao analisarmos o desempenho do NFS no diagnóstico de fibrose avançada, o ponto de corte de <-1,455 excluiu fibrose avançada com sensibilidade 59,4%, especificidade 51%, VPP 11%, VPN 92,4% e acurácia 51,7%. Entretanto, o ponto de corte de 0,676 para fibrose avançada apresentou sensibilidade de 21,9%, especificidade 83%, VPP 11,7%, VPN 91,2% e acurácia 77,3%. A AUROC foi de 0,54 (P=0,480). CONCLUSÃO: O TyG Index não apresentou bom desempenho para o diagnóstico e estadiamento da esteatose simples e da EHNA. Entretanto, foi capaz de excluir fibrose avançada em pacientes obesos candidatos a cirurgia bariátrica. BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVETo analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODSThis is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTSA total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSIONTyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery. |
Author | MATTOS, Angelo Zambam de DE CARLI, Luiz Alberto MATTOS, Angelo Alves de TOVO, Cristiane Valle CORAL, Gabriela Perdomo SMIDERLE, Carla Alessandra |
AuthorAffiliation | Santa Casa de Misericórdia de Porto Alegre Universidade Federal de Ciências da Saúde de Porto Alegre |
AuthorAffiliation_xml | – name: Universidade Federal de Ciências da Saúde de Porto Alegre – name: Santa Casa de Misericórdia de Porto Alegre |
Author_xml | – sequence: 1 givenname: Carla Alessandra orcidid: 0000-0002-2873-7069 surname: SMIDERLE fullname: SMIDERLE, Carla Alessandra organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil – sequence: 2 givenname: Gabriela Perdomo orcidid: 0000-0003-4318-2871 surname: CORAL fullname: CORAL, Gabriela Perdomo organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil – sequence: 3 givenname: Luiz Alberto orcidid: 0000-0001-8875-9908 surname: DE CARLI fullname: DE CARLI, Luiz Alberto organization: Santa Casa de Misericórdia de Porto Alegre, Brasil – sequence: 4 givenname: Angelo Alves de orcidid: 0000-0003-2417-9765 surname: MATTOS fullname: MATTOS, Angelo Alves de organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil – sequence: 5 givenname: Angelo Zambam de orcidid: 0000-0002-3063-0199 surname: MATTOS fullname: MATTOS, Angelo Zambam de organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil – sequence: 6 givenname: Cristiane Valle orcidid: 0000-0002-7932-5937 surname: TOVO fullname: TOVO, Cristiane Valle organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil |
BookMark | eNo9UU1r3DAQFSWFbpL-hvrYizf68oeOrq11BY4d1g60UBCSVipenFVqZQ_997W7YWcOAzPvvRne3IKbkz9ZAL4guEUJgw8BQkhjnEOyxRAjuEaM6QewQWmWxxQjdgM2V9AncBvCEUJMGUs34NcT3--6_WNR8qjbRcNe1M3Pku9FxeO6eS67nkeirfiPqGujShR12_Wij4q2ivqhqEVbr7S22DXVgou6b3whPBWD4O3Q34OPTk3Bfn6vd-B5x4fye9x0tSiLJjYkYTRmNksh1SrVGULMOERcjlhClU5IYjXT2DrklDmQZW5RliPMqIEMWUcOOtfkDoiL7sGro3ydxxc1_5VejfJ_w8-_pZrfRjNZmTqUJc5BumaONMsVIxoZ6OzB5owuWtuLVjCjnbw8-vN8Wo6X_WqhXC18txlDiAhbCF8vhNfZ_znb8CZfxmDsNKmT9ecgcUIZhoTSVTu7QM3sQ5itu96KoFyfKcN1ibw-U2JK_gGwnYdx |
CitedBy_id | crossref_primary_10_3390_molecules28155645 crossref_primary_10_3390_nu14234969 crossref_primary_10_1186_s12876_024_03164_4 crossref_primary_10_3389_fendo_2022_1043169 crossref_primary_10_1186_s12933_022_01548_y crossref_primary_10_1080_00365521_2024_2305268 crossref_primary_10_3390_jpm13050830 |
Cites_doi | 10.1007/s00535-015-1114-8 10.1016/j.soard.2014.06.015 10.1186/s12944-017-0409-6 10.1007/s11695-017-2829-9 10.1002/hep.20701 10.1002/hep.28431 10.1016/j.aohep.2018.09.003 10.1186/s12944-018-0913-3 10.1111/apt.12963 10.1097/MEG.0000000000001519 10.1002/hep.21496 10.1016/j.soard.2019.01.035 10.1016/j.cgh.2009.05.033 10.1016/j.soard.2015.11.011 10.1002/hep.29367 10.1016/j.jhep.2019.06.021 10.3390/ijms161025552 10.1053/j.gastro.2014.11.039 10.1089/met.2008.0034 10.1001/archsurg.138.11.1240 10.1053/j.gastro.2010.09.038 10.1016/S0168-8278(18)31946-9 10.1038/s41395-018-0088-6 |
ContentType | Journal Article |
Copyright | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright_xml | – notice: This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
DBID | AAYXX CITATION 7X8 GPN DOA |
DOI | 10.1590/s0004-2803.202100000-24 |
DatabaseName | CrossRef MEDLINE - Academic SciELO Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Avaliação do desempenho do índice triglicerídeo-glicose no diagnóstico e estadiamento da DHGNA em pacientes obesos |
EISSN | 1678-4219 |
EndPage | 144 |
ExternalDocumentID | oai_doaj_org_article_6f175ff04040481b98a93b1c0fede894 S0004_28032021000200139 10_1590_s0004_2803_202100000_24 |
GroupedDBID | 23N 2WC 53G 5GY 5VS 6J9 AAYXX ABXHO ADBBV ALMA_UNASSIGNED_HOLDINGS APOWU AZFZN BAWUL BCNDV C1A CITATION CS3 DIK E3Z EBS EJD F5P GROUPED_DOAJ GX1 IPNFZ KQ8 M~E OK1 P2P RIG RNS RSC SCD XSB ZXP 7X8 GPN |
ID | FETCH-LOGICAL-c3594-9e7604ba6b7119cf13f81954ab535eb9b2ef1facd3711e1781294c091ef3db8b3 |
IEDL.DBID | DOA |
ISSN | 0004-2803 1678-4219 |
IngestDate | Tue Oct 22 15:06:53 EDT 2024 Tue Nov 19 21:47:51 EST 2024 Fri Jun 28 12:02:29 EDT 2024 Fri Aug 23 03:21:44 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | nonalcoholic steatohepatitis hepatopatia gordurosa não-alcoólica cirurgia bariátrica Obesity nonalcoholic fatty liver disease NAFLD esteatose hepática bariatric surgery fatty liver Obesidade esteato-hepatite |
Language | English |
License | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. http://creativecommons.org/licenses/by-nc/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3594-9e7604ba6b7119cf13f81954ab535eb9b2ef1facd3711e1781294c091ef3db8b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-4318-2871 0000-0001-8875-9908 0000-0002-7932-5937 0000-0002-2873-7069 0000-0003-2417-9765 0000-0002-3063-0199 |
OpenAccessLink | https://doaj.org/article/6f175ff04040481b98a93b1c0fede894 |
PQID | 2549203444 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6f175ff04040481b98a93b1c0fede894 scielo_journals_S0004_28032021000200139 proquest_miscellaneous_2549203444 crossref_primary_10_1590_s0004_2803_202100000_24 |
PublicationCentury | 2000 |
PublicationDate | 20210601 |
PublicationDateYYYYMMDD | 2021-06-01 |
PublicationDate_xml | – month: 06 year: 2021 text: 20210601 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Arquivos de gastroenterologia |
PublicationTitleAlternate | Arq. Gastroenterol |
PublicationYear | 2021 |
Publisher | Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) |
Publisher_xml | – name: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE – name: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) |
References | Simental-Mendía LE (ref16) 2008; 6 Tovo C V. (ref25) 2019; 18 Faure S (ref14) 2018; 68 Younossi ZM (ref4) 2019; 71 Al de Carli M (ref24) 2020; 32 Angulo P (ref11) 2007; 45 Wong RJ (ref7) 2015; 148 Seki Y (ref19) 2016; 51 Losekann A (ref6) 2015; 16 Simental-Mendía LE (ref13) 2016; 15 Shah AG (ref12) 2009; 7 Haflidadottir S (ref8) 2014; 27 Younossi ZM (ref1) 2016; 64 De Cleva R (ref26) 2016; 12 Subichin M (ref2) 2015; 11 Williams CD (ref5) 2011; 140 Fedchuk L (ref22) 2014; 40 Kruger FC (ref10) 2011; 101 Noureddin M (ref9) 2018; 113 Cazzo E (ref23) 2018; 28 Kleiner DE (ref15) 2005; 41 Udelsman B V. (ref18) 2019; 15 Zheng R (ref20) 2018; 17 Chalasani N (ref3) 2018; 67 Beymer C (ref17) 2003; 138 Zhang S (ref21) 2017; 16 Younossi, ZM; Koenig, AB; Abdelatif, D; Fazel, Y; Henry, L; Wymer, M 2016; 64 Beymer, C; Kowdley K, V; Larson, A; Edmonson, P; Dellinger, EP; Flum, DR 2003; 138 Zhang, S; Du, T; Zhang, J; Lu, H; Lin, X; Xie, J 2017; 16 Simental-Mendía, LE; Simental-Mendía, E; Rodríguez-Hernández, H; Rodríguez-Morán, M; Guerrero-Romero, F 2016; 15 Angulo, P; Hui, JM; Marchesini, G; Bugianesi, E; George, J; Farrell, GC 2007; 45 Fedchuk, L; Nascimbeni, F; Pais, R; Charlotte, F; Housset, C; Ratziu, V 2014; 40 Seki, Y; Kakizaki, S; Horiguchi, N; Hashizume, H; Tojima, H; Yamazaki, Y 2016; 51 Subichin, M; Clanton, J; Makuszewski, M; Bohon, A; Zografakis, JG; Dan, A 2015; 11 Wong, RJ; Aguilar, M; Cheung, R; Perumpail, RB; Harrison, SA; Younossi, ZM 2015; 148 Shah, AG; Lydecker, A; Murray, K; Tetri, BN; Contos, MJ; Sanyal, AJ 2009; 7 Faure, S; Benjamin, R; Ramos, J; Medhi, S; David, N; Anne, L 2018; 68 Al, de Carli M; de Carli, LA; Correa, MB; Junqueira, G; Tovo, CV; Coral, GP 2020; 32 Simental-Mendía, LE; Rodríguez-Morán, M; Guerrero-Romero, F 2008; 6 Losekann, A; Weston, A; de Mattos, A; Tovo, C; de Carli, L; Espindola, M 2015; 16 Noureddin, M; Vipani, A; Bresee, C; Todo, T; Kim, IK; Alkhouri, N 2018; 113 De Cleva, R; Duarte, LF; Crenitte, MRF; De Oliveira, CPM; Pajecki, D; Santo, MA 2016; 12 Younossi, ZM; Golabi, P; de Avila, L; Paik, JM; Srishord, M; Fukui, N 2019; 71 Chalasani, N; Younossi, Z; Lavine, JE; Charlton, M; Cusi, K; Rinella, M 2018; 67 Kruger, FC; Daniels, CR; Kidd, M; Swart, G; Brundyn, K; van Rensburg, C 2011; 101 Haflidadottir, S; Jonasson, JG; Norland, H; Einarsdottir, SO; Kleiner, DE; Lund, SH 2014; 27 Williams, CD; Stengel, J; Asike, MI; Torres, DM; Shaw, J; Contreras, M 2011; 140 Udelsman B, V.; Corey, KE; Lindvall, C; Gee, DW; Meireles, OR; Hutter, MM 2019; 15 Zheng, R; Du, Z; Wang, M; Mao, Y; Mao, W 2018; 17 Kleiner, DE; Brunt, EM; Van Natta, M; Behling, C; Contos, MJ; Cummings, OW 2005; 41 Cazzo, E; Jimenez, LS; Gestic, MA; Utrini, MP; Chaim, FHM; Chaim, FDM 2018; 28 Tovo C, V.; Villela-Nogueira, CA; Leite, NC; Panke, CL; Port, GZ; Fernandes, S 2019; 18 |
References_xml | – volume: 51 start-page: 281 year: 2016 ident: ref19 article-title: Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery publication-title: J Gastroenterol doi: 10.1007/s00535-015-1114-8 contributor: fullname: Seki Y – volume: 11 start-page: 137 year: 2015 ident: ref2 article-title: Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2014.06.015 contributor: fullname: Subichin M – volume: 16 start-page: 15 year: 2017 ident: ref21 article-title: The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease publication-title: Lipids Health Dis doi: 10.1186/s12944-017-0409-6 contributor: fullname: Zhang S – volume: 28 start-page: 187 year: 2018 ident: ref23 article-title: Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features publication-title: Obes Surg doi: 10.1007/s11695-017-2829-9 contributor: fullname: Cazzo E – volume: 41 start-page: 1313 year: 2005 ident: ref15 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.20701 contributor: fullname: Kleiner DE – volume: 101 start-page: 477 year: 2011 ident: ref10 article-title: APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH publication-title: S Afr Med J contributor: fullname: Kruger FC – volume: 64 start-page: 73 year: 2016 ident: ref1 article-title: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology doi: 10.1002/hep.28431 contributor: fullname: Younossi ZM – volume: 18 start-page: 445 year: 2019 ident: ref25 article-title: Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD) publication-title: Ann Hepatol doi: 10.1016/j.aohep.2018.09.003 contributor: fullname: Tovo C V. – volume: 17 start-page: 262 year: 2018 ident: ref20 article-title: A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease publication-title: Lipids Health Dis doi: 10.1186/s12944-018-0913-3 contributor: fullname: Zheng R – volume: 40 start-page: 1209 year: 2014 ident: ref22 article-title: Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12963 contributor: fullname: Fedchuk L – volume: 32 start-page: 420 year: 2020 ident: ref24 article-title: Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0000000000001519 contributor: fullname: Al de Carli M – volume: 45 start-page: 846 year: 2007 ident: ref11 article-title: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD publication-title: Hepatology doi: 10.1002/hep.21496 contributor: fullname: Angulo P – volume: 15 start-page: 843 year: 2019 ident: ref18 article-title: Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2019.01.035 contributor: fullname: Udelsman B V. – volume: 7 start-page: 1104 year: 2009 ident: ref12 article-title: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2009.05.033 contributor: fullname: Shah AG – volume: 12 start-page: 862 year: 2016 ident: ref26 article-title: Use of noninvasive markers to predict advanced fibrosis/cirrhosis in severe obesity publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2015.11.011 contributor: fullname: De Cleva R – volume: 67 start-page: 328 year: 2018 ident: ref3 article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology doi: 10.1002/hep.29367 contributor: fullname: Chalasani N – volume: 71 start-page: 793 year: 2019 ident: ref4 article-title: The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis publication-title: J Hepatol doi: 10.1016/j.jhep.2019.06.021 contributor: fullname: Younossi ZM – volume: 16 start-page: 25552 year: 2015 ident: ref6 article-title: Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients publication-title: Int J Mol Sci doi: 10.3390/ijms161025552 contributor: fullname: Losekann A – volume: 148 start-page: 547 year: 2015 ident: ref7 article-title: Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.11.039 contributor: fullname: Wong RJ – volume: 15 start-page: 715 year: 2016 ident: ref13 article-title: The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women publication-title: Ann Hepatol contributor: fullname: Simental-Mendía LE – volume: 6 start-page: 299 year: 2008 ident: ref16 article-title: The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects publication-title: Metab Syndr Relat Disord doi: 10.1089/met.2008.0034 contributor: fullname: Simental-Mendía LE – volume: 138 start-page: 1240 year: 2003 ident: ref17 article-title: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery publication-title: Arch Surg doi: 10.1001/archsurg.138.11.1240 contributor: fullname: Beymer C – volume: 140 start-page: 124 year: 2011 ident: ref5 article-title: Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.09.038 contributor: fullname: Williams CD – volume: 68 start-page: S835 year: 2018 ident: ref14 article-title: The triglycerides and glucose (TyG) index: a new marker associated with Non Alcoholic Steatohepatitis (NASH) and fibrosis in obese patients? publication-title: J Hepatol doi: 10.1016/S0168-8278(18)31946-9 contributor: fullname: Faure S – volume: 113 start-page: 1649 year: 2018 ident: ref9 article-title: NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances publication-title: Am J Gastroenterol doi: 10.1038/s41395-018-0088-6 contributor: fullname: Noureddin M – volume: 27 start-page: 14 year: 2014 ident: ref8 article-title: Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease publication-title: BMC Gastroenterol contributor: fullname: Haflidadottir S – volume: 41 start-page: 1313 year: 2005 end-page: 1321 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology contributor: fullname: Kleiner, DE; Brunt, EM; Van Natta, M; Behling, C; Contos, MJ; Cummings, OW – volume: 12 start-page: 862 year: 2016 end-page: 867 article-title: Use of noninvasive markers to predict advanced fibrosis/cirrhosis in severe obesity publication-title: Surg Obes Relat Dis contributor: fullname: De Cleva, R; Duarte, LF; Crenitte, MRF; De Oliveira, CPM; Pajecki, D; Santo, MA – volume: 17 start-page: 262 year: 2018 end-page: 262 article-title: A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease publication-title: Lipids Health Dis contributor: fullname: Zheng, R; Du, Z; Wang, M; Mao, Y; Mao, W – volume: 16 start-page: 25552 year: 2015 end-page: 25559 article-title: Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients publication-title: Int J Mol Sci contributor: fullname: Losekann, A; Weston, A; de Mattos, A; Tovo, C; de Carli, L; Espindola, M – volume: 45 start-page: 846 year: 2007 end-page: 854 article-title: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD publication-title: Hepatology contributor: fullname: Angulo, P; Hui, JM; Marchesini, G; Bugianesi, E; George, J; Farrell, GC – volume: 32 start-page: 420 year: 2020 end-page: 425 article-title: Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease publication-title: Eur J Gastroenterol Hepatol contributor: fullname: Al, de Carli M; de Carli, LA; Correa, MB; Junqueira, G; Tovo, CV; Coral, GP – volume: 113 start-page: 1649 year: 2018 end-page: 1659 article-title: NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances publication-title: Am J Gastroenterol contributor: fullname: Noureddin, M; Vipani, A; Bresee, C; Todo, T; Kim, IK; Alkhouri, N – volume: 28 start-page: 187 year: 2018 end-page: 194 article-title: Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features publication-title: Obes Surg contributor: fullname: Cazzo, E; Jimenez, LS; Gestic, MA; Utrini, MP; Chaim, FHM; Chaim, FDM – volume: 140 start-page: 124 year: 2011 end-page: 131 article-title: Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study publication-title: Gastroenterology contributor: fullname: Williams, CD; Stengel, J; Asike, MI; Torres, DM; Shaw, J; Contreras, M – volume: 64 start-page: 73 year: 2016 end-page: 84 article-title: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology contributor: fullname: Younossi, ZM; Koenig, AB; Abdelatif, D; Fazel, Y; Henry, L; Wymer, M – volume: 18 start-page: 445 year: 2019 end-page: 449 article-title: Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD) publication-title: Ann Hepatol contributor: fullname: Tovo C, V.; Villela-Nogueira, CA; Leite, NC; Panke, CL; Port, GZ; Fernandes, S – volume: 15 start-page: 843 year: 2019 end-page: 849 article-title: Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery publication-title: Surg Obes Relat Dis contributor: fullname: Udelsman B, V.; Corey, KE; Lindvall, C; Gee, DW; Meireles, OR; Hutter, MM – volume: 6 start-page: 299 year: 2008 end-page: 304 article-title: The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects publication-title: Metab Syndr Relat Disord contributor: fullname: Simental-Mendía, LE; Rodríguez-Morán, M; Guerrero-Romero, F – volume: 40 start-page: 1209 year: 2014 end-page: 1222 article-title: Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease publication-title: Aliment Pharmacol Ther contributor: fullname: Fedchuk, L; Nascimbeni, F; Pais, R; Charlotte, F; Housset, C; Ratziu, V – volume: 7 start-page: 1104 year: 2009 end-page: 1112 article-title: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease publication-title: Clin Gastroenterol Hepatol contributor: fullname: Shah, AG; Lydecker, A; Murray, K; Tetri, BN; Contos, MJ; Sanyal, AJ – volume: 11 start-page: 137 year: 2015 end-page: 141 article-title: Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery publication-title: Surg Obes Relat Dis contributor: fullname: Subichin, M; Clanton, J; Makuszewski, M; Bohon, A; Zografakis, JG; Dan, A – volume: 67 start-page: 328 year: 2018 end-page: 357 article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology contributor: fullname: Chalasani, N; Younossi, Z; Lavine, JE; Charlton, M; Cusi, K; Rinella, M – volume: 27 start-page: 14 year: 2014 end-page: 166 article-title: Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease publication-title: BMC Gastroenterol contributor: fullname: Haflidadottir, S; Jonasson, JG; Norland, H; Einarsdottir, SO; Kleiner, DE; Lund, SH – volume: 51 start-page: 281 year: 2016 end-page: 289 article-title: Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery publication-title: J Gastroenterol contributor: fullname: Seki, Y; Kakizaki, S; Horiguchi, N; Hashizume, H; Tojima, H; Yamazaki, Y – volume: 68 start-page: S835 year: 2018 end-page: S835 article-title: The triglycerides and glucose (TyG) index: a new marker associated with Non Alcoholic Steatohepatitis (NASH) and fibrosis in obese patients? publication-title: J Hepatol contributor: fullname: Faure, S; Benjamin, R; Ramos, J; Medhi, S; David, N; Anne, L – volume: 71 start-page: 793 year: 2019 end-page: 801 article-title: The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis publication-title: J Hepatol contributor: fullname: Younossi, ZM; Golabi, P; de Avila, L; Paik, JM; Srishord, M; Fukui, N – volume: 148 start-page: 547 year: 2015 end-page: 555 article-title: Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States publication-title: Gastroenterology contributor: fullname: Wong, RJ; Aguilar, M; Cheung, R; Perumpail, RB; Harrison, SA; Younossi, ZM – volume: 16 start-page: 15 year: 2017 end-page: 15 article-title: The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease publication-title: Lipids Health Dis contributor: fullname: Zhang, S; Du, T; Zhang, J; Lu, H; Lin, X; Xie, J – volume: 101 start-page: 477 year: 2011 end-page: 480 article-title: APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH publication-title: S Afr Med J contributor: fullname: Kruger, FC; Daniels, CR; Kidd, M; Swart, G; Brundyn, K; van Rensburg, C – volume: 15 start-page: 715 year: 2016 end-page: 720 article-title: The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women publication-title: Ann Hepatol contributor: fullname: Simental-Mendía, LE; Simental-Mendía, E; Rodríguez-Hernández, H; Rodríguez-Morán, M; Guerrero-Romero, F – volume: 138 start-page: 1240 year: 2003 end-page: 1244 article-title: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery publication-title: Arch Surg contributor: fullname: Beymer, C; Kowdley K, V; Larson, A; Edmonson, P; Dellinger, EP; Flum, DR |
SSID | ssj0024996 |
Score | 2.2914486 |
Snippet | ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside... BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In... |
SourceID | doaj scielo proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database |
StartPage | 139 |
SubjectTerms | bariatric surgery fatty liver GASTROENTEROLOGY & HEPATOLOGY NAFLD nonalcoholic fatty liver disease nonalcoholic steatohepatitis Obesity |
Title | PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS |
URI | https://search.proquest.com/docview/2549203444 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032021000200139&lng=en&tlng=en https://doaj.org/article/6f175ff04040481b98a93b1c0fede894 |
Volume | 58 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwFLQoB8SloqUVS1tkJKSeojqx8-Fj2HhDxJIgEiSQkKz464QW1GX_f5-T7Kqceuk1sa2nebbmjW2NEbqgPWWx1jFUbhoESq-yQAENBWGmQqO4icyw4XbVpvVDVghvk7N76svfCRvtgUfgfiUOCM45mGvMW5sonvWcqlATZ43N-OgESpKtmNq67EEZP93mijnxlqGEBf4hJlCE0bClTYKIveOiwbL_fZ3pSej5b75ZHKGPU6GI8zHAT2jPrj6jg5vpKPwYPd2KO1BwN_lc4GaBu7uqXD7OQZYVIiiX9_OmFbiqC_GAmxoXVV7WTVu1OK8L3HZ5WdWl71bni2UB7XBzKaDDbd5Vou7aL-h-Ibr5VTA9lRBoGnMWcJsmhKk-UWkYcu1C6vwBGWAf09gqriLrQtdrQ-G_DVOgdc401ArWUaMyRb-i_dXLyp4grIH0tSIJoZlmfW9A8qTeJjCBvlZzM0NkC5p8HR0xpFcSgLMccJYeZ7nDWUZshi49uLvm3tJ6-ACJllOi5b8SPUPn29RIWAL-XKNf2ZfNWnqNG3nrQmjzc8yZnFbiWra7kKaIoqHqPf0fIX1Dh37Q8ebYd7T_9ntjf6APa7M5g-lYXZ8Nk_IPQK3VkA |
link.rule.ids | 230,315,782,786,866,887,2106,27933,27934 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PERFORMACE+OF+TRIGLYCERIDE-GLUCOSE+INDEX+ON+DIAGNOSIS+AND+STAGING+OF+NAFLD+IN+OBESE+PATIENTS&rft.jtitle=Arquivos+de+gastroenterologia&rft.au=Smiderle%2C+Carla+Alessandra&rft.au=Coral%2C+Gabriela+Perdomo&rft.au=DE+Carli%2C+Luiz+Alberto&rft.au=Mattos%2C+Angelo+Alves+de&rft.date=2021-06-01&rft.eissn=1678-4219&rft.volume=58&rft.issue=2&rft.spage=139&rft.epage=144&rft_id=info:doi/10.1590%2FS0004-2803.202100000-24&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0004-2803&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0004-2803&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0004-2803&client=summon |